Experimental cell therapy offers hope for Hard-to-Treat blood disorder
NCT ID NCT07075484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new cell therapy called YTS109 in 7 people with a severe type of autoimmune anemia that did not get better after at least 3 other treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the disease. The main goal was to check if the treatment is safe and to see if it can help control the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Engineered immune cells take aim at stubborn blood disorder
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New study aims to unlock the secrets of Children's rare blood diseases
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial